Polymorphisms in the 3′-UTR of ERCC1 and in the coding regions of the ERCC2/XPD and XRCC1 genes have been associated with disease prognosis and response to cisplatin in SCCHN patients [28]. This evidence concerns the gene ERCC2 and head and neck squamous cell carcinoma.